Last reviewed · How we verify
ALC-2203-2
ALC-2203-2 is a GPR84 agonist Small molecule drug developed by Korea Arlico Pharm. Co., Ltd. It is currently in Phase 2 development for Treatment of inflammatory diseases.
ALC-2203-2 is a selective and potent agonist of the GPR84 receptor.
ALC-2203-2 is a selective and potent agonist of the GPR84 receptor. Used for Treatment of inflammatory diseases.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ALC-2203-2 |
|---|---|
| Sponsor | Korea Arlico Pharm. Co., Ltd |
| Drug class | GPR84 agonist |
| Target | GPR84 |
| Modality | Small molecule |
| Therapeutic area | Inflammation |
| Phase | Phase 2 |
Mechanism of action
GPR84 is a G protein-coupled receptor that plays a role in the regulation of inflammation and immune responses. Activation of GPR84 by ALC-2203-2 may lead to anti-inflammatory effects and potential therapeutic benefits.
Approved indications
- Treatment of inflammatory diseases
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALC-2203-2 CI brief — competitive landscape report
- ALC-2203-2 updates RSS · CI watch RSS
- Korea Arlico Pharm. Co., Ltd portfolio CI
Frequently asked questions about ALC-2203-2
What is ALC-2203-2?
How does ALC-2203-2 work?
What is ALC-2203-2 used for?
Who makes ALC-2203-2?
What drug class is ALC-2203-2 in?
What development phase is ALC-2203-2 in?
What are the side effects of ALC-2203-2?
What does ALC-2203-2 target?
Related
- Drug class: All GPR84 agonist drugs
- Target: All drugs targeting GPR84
- Manufacturer: Korea Arlico Pharm. Co., Ltd — full pipeline
- Therapeutic area: All drugs in Inflammation
- Indication: Drugs for Treatment of inflammatory diseases
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing